GUANGZHOU, China, Jan. 05, 2026 — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), which applies next generation sequencing (NGS) technology in precision oncology, today announced that its founder, chairman, and CEO, Mr. Yusheng Han, has acquired US$811,721.28 worth of the Company’s American Depositary Shares (ADSs) in the open market. This transaction adhered to all relevant rules, regulations, and the Company’s insider trading policy. The purchase reflects Mr. Han’s confidence in the Company’s business and future outlook.
Depending on market conditions and in compliance with applicable regulations, Mr. Han may acquire additional ADSs through open-market transactions, privately negotiated deals, block trades, or other lawful methods. The specifics of any future purchases will be influenced by several factors, including the stipulations of Rules 10b-18 and 10b5-1 under the Securities Exchange Act of 1934, alongside the Company’s insider trading policy.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR) is dedicated to guarding life through science, specializing in the use of next generation sequencing (NGS) technology for precision oncology. The Company operates two primary business segments: i) NGS-based therapy selection testing for patients with late-stage cancer, and ii) cancer early detection, which has progressed from proof-of-concept research and development to the stage of clinical validation.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Contact: IR@brbiotech.com
